iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2092

Identifiers

  • Canonical SMILES: 
    CC[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@](C)(CCCCN(C)C(=O)[C@H](NC1=O)c1ccc(F)cc1)NC(=O)C(C)C
  • IUPAC name: 
    N-[(3R,6S,9S,12R)-9-(3-carbamimidamidopropyl)-6-ethyl-3-(4-fluorophenyl)-1,12-dimethyl-2,5,8,11-tetraoxo-1,4,7,10-tetraazacyclohexadecan-12-yl]-2-methylpropanamide
  • InChi: 
    InChI=1S/C30H47FN8O5/c1-6-21-25(41)37-23(19-11-13-20(31)14-12-19)27(43)39(5)17-8-7-15-30(4,38-24(40)18(2)3)28(44)36-22(26(42)35-21)10-9-16-34-29(32)33/h11-14,18,21-23H,6-10,15-17H2,1-5H3,(H,35,42)(H,36,44)(H,37,41)(H,38,40)(H4,32,33,34)/t21-,22-,23+,30+/m0/s1
  • InChiKey: 
    JGIIYJOEBDGPQO-CXDLDTBJSA-N

External links


71586179
CHEMBL4117068

External search

Bibliography (1)

Publication Name
Karatas Hacer, Li Yangbing, Liu Liu, Ji Jiao, Lee Shirley, Chen Yong, Yang Jiuling, Huang Liyue, Bernard Denzil, Xu Jing, Townsend Elizabeth C., Cao Fang, Ran Xu, Li Xiaoqin, Wen Bo, Sun Duxin, Stuckey Jeanne A, Lei Ming, Dou Yali, Wang Shaomeng. . Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction Journal of Medicinal Chemistry. 4

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
3 3 0 0

Targets

PPI family Best activity Diseases MMoA
WDR5/MLL 9.00 lymphoid leukemia (disease) Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 618.37 g/mol
HBA 13
HBD 8
HBA + HBD 21
AlogP 0.04
TPSA 200.35
RB 8
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 3 3 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b01796 4 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 8.80
10.1021/acs.jmedchem.6b01796 4 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pKi (inhibition constant, -log10) 9.00
10.1021/acs.jmedchem.6b01796 4 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay AlphaLISA pIC50 (half maximal inhibitory concentration, -log10) 6.86
10.1021/acs.jmedchem.6b01796 4 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition MOLM-13 MOLM-13 pIC50 (half maximal inhibitory concentration, -log10) 4.79
10.1021/acs.jmedchem.6b01796 4 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition MV4-11 MV4-11 pIC50 (half maximal inhibitory concentration, -log10) 5.28
10.1021/acs.jmedchem.6b01796 4 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition HL-60 HL60 pIC50 (half maximal inhibitory concentration, -log10) 4.22
Ta Structure Name Drugbank ID
0.7109 CR665 DB05155
0.6897 D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide DB07027
0.6786 D-phenylalanyl-N-benzyl-L-prolinamide DB07143
0.6555 D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide DB07005
0.6552 D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide DB07133
0.6429 (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide DB06850
0.6429 N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06858
0.6429 PZ-128 DB11839
0.6396 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06947
0.6396 D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06996
0.6372 N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06853
0.6372 (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide DB07095
0.6372 (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide DB07131
0.6323 Motixafortide DB14939
0.6281 D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide DB06919